Search results

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.

Result type

Technology appraisal guidance

Published

28 March 2018

Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.

Result type

Technology appraisal guidance

Published

14 December 2022

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

3 October 2018

Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

10 April 2024

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

9 August 2017

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.

Result type

Technology appraisal guidance

Published

1 November 2023

NICE is unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission.

Result type

Technology appraisal guidance

Published

20 April 2022

In development [GID-TA11613] Expected publication date: TBC

Result type

Technology appraisal guidance

Status

In development

Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

Result type

Technology appraisal guidance

Published

12 December 2018

Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

11 January 2023

Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations in people 12 years and older.

Result type

Technology appraisal guidance

Published

3 November 2021

Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

24 January 2018

In development [GID-TA11186] Expected publication date: TBC

Result type

Technology appraisal guidance

Status

In development

Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

2 September 2020

Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

30 September 2020